You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 105 No. 1, JANUARY 1960 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL ARTICLES
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati
What's this?

Ristocetin-Induced Thrombocytopenia: Site and Mechanism of Action

CAPT. EUGENE J. GANGAROSA, MC; THELMA R. JOHNSON, B.S.; CAPT. HAROLD S. RAMOS, MC

AMA Arch Intern Med. 1960;105(1):83-89.

Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Ristocetin is a new antimicrobial agent consisting of two antibiotics, ristocetin A and B. These components have been separated from the fermentation broth of the actinomycete species Nocardia lurida. Advantages of this drug include the lack of development of resistant organisms and an absence of cross-resistance with other antibiotics. Several investigators have demonstrated the merit of ristocetin in problems of severe staphylococcal and enterococcal infections.1-4

In previous publications5,6 the development of thrombocytopenia in four patients during ristocetin therapy was noted. Platelet depression was related to high doses of ristocetin and could be reversed by discontinuing or reducing the dose. Individuals with renal insufficiency were more susceptible to thrombocytopenia due to drug accumulation.

The purpose of this publication is to report on the subsequent clinical experience and laboratory findings, and to relate these observations to the mechanism and site of action of ristocetin-induced thrombocyto-penia. Five patients have been treated with ristocetin . . . [Full Text PDF of this Article]


Author Affiliations

U.S. Army; U.S.A.F.

From the Department of Medicine, Walter Reed Army Hospital, and the Department of Hematology and Division of Communicable Disease, Walter Reed Army Institute of Research.; Captain Gangarosa is Clinical Liaison Officer, Division of Communicable Disease, Walter Reed Army Institute of Research and Walter Reed Army Hospital; Miss Johnson is Research Assistant, Department of Hematology, Walter Reed Army Institute of Research, and Captain Ramos is Research Fellow, Department of Hematology, Walter Reed Army Institute of Research.


Footnotes

Submitted for publication May 20, 1959.

Kindly supplied as Spontin by Abbott Laboratories, North Chicago, Illinois.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1960 American Medical Association. All Rights Reserved.